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Tumour suppressorOur recent study of the microRNA expression signature of prostate cancer (PCa) revealed that
microRNA-224 (miR-224) is signiﬁcantly downregulated in PCa tissues. Here, we found that restora-
tion of miR-224 signiﬁcantly inhibits PCa cell migration and invasion. Additionally, we found that
oncogenic TPD52 is a direct target of miR-224 regulation. Silencing of the TPD52 gene signiﬁcantly
inhibits cancer cell migration and invasion. Moreover, TPD52 expression is upregulated in cancer
tissues and negatively correlates with miR-224 expression. We conclude that loss of tumour-sup-
pressive miR-224 enhances cancer cell migration and invasion in PCa through direct regulation of
oncogenic TPD52.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction (miRNAs) are endogenous small ncRNA molecules (19–22 bases inProstate cancer (PCa) is the most frequently diagnosed cancer
and the second leading cause of cancer-related death among men
in developed countries [1]. Most patients are initially responsive
to androgen-deprivation therapy (ADT), but their cancers eventu-
ally become resistant to ADT and progress to castration-resistant
prostate cancer (CRPC). CRPC is difﬁcult to treat, and most clinical
trials of therapies to treat advanced PCa have shown limited bene-
ﬁts, with disease progression and metastasis to the skeleton or
other sites [2,3]. Therefore, understanding the molecular mecha-
nisms of the metastatic pathways underlying PCa using genomic
approaches would help to elucidate the mechanisms of PCa
progression.
The discovery of non-coding RNAs (ncRNAs) in the human gen-
ome was an important conceptual breakthrough in the post-
genome sequencing era [4]. Improved understanding of ncRNAs
is necessary for continued progress in cancer research. MicroRNAslength) that regulate the expression of protein-coding genes by
repressing translation or cleaving RNA transcripts in a sequence-
speciﬁc manner [5]. A signiﬁcant amount of evidence suggests that
miRNAs are aberrantly expressed in many human cancers and play
signiﬁcant roles in the initiation, development, and metastasis of
those cancers [6].
It is believed that normal regulatory mechanisms can be dis-
rupted by the aberrant expression of tumour-suppressive or onco-
genic miRNAs in cancer cells. Therefore, identiﬁcation of aberrantly
expressed miRNAs is an important ﬁrst step toward elucidating the
details of miRNA-mediated oncogenic pathways. Based on this
background, we have previously evaluated miRNA expression sig-
natures using PCa clinical specimens [7] and investigated the roles
of miRNAs in PCa oncogenesis using differentially expressed miR-
NAs [8–10].
Our miRNA signature of PCa showed that miR-224 was signiﬁ-
cantly reduced in cancer tissues, suggesting that miR-224 may act
as a tumour suppressor. The aim of the present study was to
investigate the functional signiﬁcance of miR-224 and to identify
the molecular targets regulated by this miRNA in PCa cells. We
found that restoration of mature miR-224 inhibited cancer cell
migration and invasion. Gene expression data and in silico data-
Table 1
Patients’ characteristics.
No. Pca or non-Pca Age (years) PSA (ng/mL) Gleason score Stage cT cN cM
1 PCa 67 244 4 + 4 D2 4 1 1
2 PCa 70 395 4 + 4 D2 3a 1 1
3 PCa 83 49.9 4 + 5 C 3a 0 0
4 PCa 68 212 4 + 4 D1 3b 1 0
5 PCa 80 589 4 + 4 D1 3b 1 0
6 PCa 72 2530 4 + 5 D2 3a 1 1
7 PCa 76 12.5 4 + 5 D2 3b 1 1
8 PCa 67 153 4 + 4 D2 4 1 1
9 PCa 82 808.8 4 + 4 D2 4 1 1
10 Pca 88 50.5 4 + 4 C 3a 0 0
11 PCa 69 3.45 4 + 3 C 3a 0 0
12 PCa 64 486 4 + 5 D2 4 1 1
13 PCa 74 60.8 5 + 5 D2 4 1 1
14 PCa 63 49.6 4 + 4 D1 3b 1 0
15 PCa 69 1060 4 + 5 D2 4 1 1
16 PCa 67 34.9 4 + 4 D2 3b 1 1
17 PCa 64 7.23 4 + 4 D1 3b 1 0
18 PCa 79 3750 4 + 4 D2 3a 0 1
19 PCa 78 1400 4 + 4 D2 3a 0 1
20 PCa 77 2640 4 + 4 D2 4 1 1
21 PCa 69 554 4 + 4 D2 3b 1 1
22 PCa 82 59.5 4 + 5 C 3b 0 0
23 PCa 70 1030 4 + 4 D2 3b 1 1
24 PCa 78 892 4 + 5 D2 4 1 1
25 PCa 86 24.2 4 + 4 C 3b 0 0
26 PCa 67 64.6 4 + 5 D2 3b 0 1
27 PCa 71 63.8 4 + 3 C 3a 0 0
28 PCa 75 22.7 4 + 4 C 3b 0 0
29 PCa 87 98.59 4 + 5 D1 4 1 0
30 PCa 78 693 4 + 4 D2 3b 1 1
31 PCa 76 97.4 4 + 4 D2 3b 1 1
32 PCa 64 1120 4 + 4 D2 4 1 1
33 PCa 78 266 4 + 4 D2 4 1 1
34 PCa 80 571 4 + 4 D2 4 1 1
35 PCa 65 277 4 + 5 D2 4 1 1
36 PCa 75 1000 4 + 5 D2 4 1 1
37 PCa 69 95.6 4 + 4 D2 4 1 1
38 PCa 66 36.08 4 + 5 D1 3a 1 0
39 PCa 72 102 4 + 4 C 3a 0 0
40 PCa 65 212 4 + 4 D2 4 1 1
41 PCa 81 11.4 4 + 4 B 2 0 0
42 PCa 73 467 4 + 4 D1 3b 1 0
43 PCa 58 482 4 + 4 D1 3b 1 0
44 PCa 73 76.4 4 + 4 C 3a 0 0
45 PCa 78 989 4 + 4 D2 4 1 1
46 PCa 73 478 4 + 3 D2 3b 0 1
47 PCa 79 63.2 4 + 5 D2 3b 1 1
48 PCa 70 248 3 + 4 D1 3a 1 0
49 PCa 81 1338 4 + 5 D2 4 0 1
50 PCa 76 12.9 4 + 5 D2 4 1 1
1 Non-PCa 69 12.2
2 Non-PCa 66 11.9
3 Non-PCa 85 10.1
4 Non-PCa 55 11.2
5 Non-PCa 67 22
6 Non-PCa 66 7.33
7 Non-PCa 69 7.92
8 Non-PCa 68 7.24
9 Non-PCa 53 4.33
10 Non-PCa 62 5.14
11 Non-PCa 63 10
12 Non-PCa 62 5.11
13 Non-PCa 74 8.3
14 Non-PCa 65 4.3
15 Non-PCa 72 5.43
16 Non-PCa 66 5.35
17 Non-PCa 67 5
18 Non-PCa 66 19.5
19 Non-PCa 63 12.9
20 Non-PCa 53 6.69
21 Non-PCa 63 5.3
22 Non-PCa 66 7.73
23 Non-PCa 57 7.3
24 Non-PCa 54 5.44
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Table 1 (continued)
No. Pca or non-Pca Age (years) PSA (ng/mL) Gleason score Stage cT cN cM
25 Non-PCa 67 5.93
26 Non-PCa 67 8.09
27 Non-PCa 60 14
28 Non-PCa 69 5.99
29 Non-PCa 60 5.6
30 Non-PCa 56 8.44
31 Non-PCa 61 8.6
32 Non-PCa 62 35.5
33 Non-PCa 73 6.02
34 Non-PCa 57 5.19
35 Non-PCa 64 4.37
36 Non-PCa 60 5.68
37 Non-PCa 63 11.4
38 Non-PCa 65 13.2
P < 0.0001
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Fig. 1. Expression of miR-224 in PCa clinical specimens. miR-224 expression levels
in PCa clinical specimens (PCa and non-PCa), normal prostate cell line (RWPE-1)
and PCa cell lines (PC3 and DU145) were measured by qRT-PCR. RNU48was used as
a housekeeping gene for normalisation.
Y. Goto et al. / FEBS Letters 588 (2014) 1973–1982 1975base analysis showed that tumour protein D52 (TPD52) was a
potential target of miR-224 regulation. TPD52 has previously been
isolated from the ampliﬁcation region of human chromosome
8q21 in prostate and breast cancer and is known to function as
an oncogene [11,12]. Silencing of the TPD52 gene resulted in signif-
icant inhibition of cell migration and invasion in PCa cells. Elucida-
tion of the cancer pathways and targets regulated by tumour-
suppressive miR-224 will provide new insights into the potential
mechanisms of oncogenesis and metastasis of PCa.
2. Materials and methods
2.1. Clinical prostate specimens and PCa cells
Clinical prostate specimens were obtained from patients admit-
ted to Teikyo University Chiba Medical Centre Hospital from 2008
to 2013. Men who were suspected to have PCa according to ele-
vated serum prostate-speciﬁc antigen (PSA) levels, digital rectal
examination, and ultrasound subsequently underwent prostate
biopsy, and 10–12 cores were obtained from each patient. A pair
of needle biopsy specimens was collected from the same region;
one specimen was subjected to pathological analysis, while theother was used for molecular analyses. If none of the prostate
biopsy cores contained cancerous cells, we categorised the patient
and tissue as non-PCa. Prostatic cancerous tissues (PCa, n = 50) and
non-cancerous tissues (non-PCa, n = 38) were used in this study.
Written consent for tissue donation for research purposes was
obtained from each patient before tissue collection. The protocol
was approved by the Institutional Review Board of Teikyo
University.
We used 2 human PCa cell lines, PC3 and DU145, as well as the
normal human prostate cell line RWPE-1, which were obtained
from the American Type Culture Collection (Manassas, VA, USA).
PC3 and DU145 cells were maintained in RPMI-1640 medium sup-
plemented with 10% foetal bovine serum in a humidiﬁed atmo-
sphere of 5% CO2 and 95% air at 37 C. RWPE-1 cells were
cultured in keratinocyte serum-free medium containing 5 ng/mL
epidermal growth factor and 50 lg/mL bovine pituitary extract.
2.2. RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol. The
quality of RNA was conﬁrmed using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA).2.3. Quantitative real-time RT-PCR (qRT-PCR)
The procedure for PCR quantiﬁcation was performed as
described previously [9,13,14]. The expression of miR-224 (Assay
ID: 002099; Applied Biosystems, Foster City, CA, USA) was analysed
by TaqMan quantitative real-time PCR and normalised to the
expression of RNU48 (Assay ID: 001006). TaqMan probes and prim-
ers for TPD52 (P/N: Hs00893105_m1; Applied Biosystems), GUSB
(the internal control; P/N: Hs00939627_m1; Applied Biosystems),
and GAPDH (the internal control; P/N: Hs02758991_g1; Applied
Biosystems) were assay-on-demand gene expression products.
2.4. Transfection with mature miRNA and small interfering RNA (si-
RNA)
The following mature miRNAs species were used in this study:
Ambion Pre-miR miRNA precursor for hsa-miR-224(A) (product ID:
PM12571; Applied Biosystems) and miRIDIAN miRNA Human hsa-
miR-224-5p-Mimic for hsa-miR-224(T) (product ID: C-300581-07;
Thermo Fisher Scientiﬁc). The following siRNAs were used: Stealth
Select RNAi siRNA; si-TPD52 (Cat No. HSS178924; Invitrogen) and
negative control miRNA/siRNA (P/N: AM17111, Applied Biosys-
tems). Transfection procedures were performed as described in
our previous report [9,13,14].
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Fig. 2. Effects of restoringmiR-224 on cell proliferation, migration, and invasion in PCa cell lines. (A) Cell proliferation was determined by XTT assay at 72 h after transfection
with miR-224 (10 nM). (B) Cell migration activity was determined by migration assay at 48 h after transfection with miR-224 (10 nM). (C) Cell invasion activity was
determined by Matrigel invasion assay at 48 h after transfection with miR-224 (10 nM). miR-224-(A): Ambion, miR-224-(T): Thermo Scientiﬁc Dharmacon. ⁄P < 0.05.
1976 Y. Goto et al. / FEBS Letters 588 (2014) 1973–19822.5. Cell proliferation, migration, and invasion assays
Cells were transfected with 10 nm miRNA or siRNA by reverse
transfection and plated in 96-well plates at 3  103 cells per well.
After 72 h, cell proliferation was determined by XTT assay using
a Cell Proliferation Kit II (Roche Applied Sciences, Tokyo, Japan),
as previously reported [9,13,14].
Cell migration activity was evaluated by wound-healing assay.
Cells were seeded in 6-well plates, and the cell monolayer was
scraped using a P-1000 micropipette tip. The initial gap length
(0 h) and residual gap length 24 h after wounding were calculated
from photomicrographs, as previously reported [9,13,14].
A cell invasion assay was carried out using modiﬁed Boyden
chambers containing Transwell-precoated Matrigel membrane ﬁl-
ter inserts with 8-lm pores in 24-well tissue culture plates, with
cells plated at 1  105 cells per well (BD Biosciences). After gentle
removal of the non-invasive cells from the ﬁlter surface of the
upper chamber, the cells that invaded to the lower side were ﬁxed
and stained with Diff-Quick (Sysmex Corporation, Kobe, Japan).
The number of cells that invaded to the lower surface was deter-
mined microscopically by counting four areas of constant size
per well, as previously reported [9,13,14].
All experiments were performed in triplicate.
2.6. Genome-wide gene expression and in silico analysis for the
identiﬁcation of genes regulated by miR-224
To identify miR-224 target genes, we used in silico analysis and
genome-wide gene expression analysis. First, we screened genes
using TargetScan Release 6.2 (http://www.targetscan.org/). Next,we attempted to identify miR-224 target genes using miR-224-
transfected PC3 and DU145 cells. A SurePrint G3 Human GE
8  60 K Microarray (Agilent Technologies, Santa Clara, CA, USA)
was used for expression proﬁling of miR-224 transfectants in com-
parison with miRNA-negative control transfectants. Genes contain-
ing putative miR-224 target sites and exhibiting downregulation in
miR-224 transfectants were listed. Furthermore, to identify upreg-
ulated genes in clinical PCa specimens, we analysed a publicly
available gene expression data set in the GEO database (accession
number: GSE29079). We merged these data sets and selected puta-
tive miR-224 target genes in this study.
2.7. Western blot analysis
Cells were harvested 72 h after transfection, and lysates were
prepared. Cell lysates (20 lg protein) were separated on Mini-
PROTEAN TGX gels (Bio-Rad, Hercules, CA, USA) and transferred
to PVDF membranes. Immunoblotting was performed with rabbit
anti-TPD52 antibodies (1:250, HPA028427, Atlas Antibodies,
Stockholm, Sweden). Anti-GAPDH antibodies (1:1000, ab8245,
Abcam) were used as an internal loading control. Membranes were
washed and incubated with anti-rabbit IgG horseradish peroxidase
(HRP)-linked antibodies (7074, Cell Signaling Technology, Danvers,
MA, USA). Complexes were visualised with Clarity Western ECL
Substrate (Bio-Rad).
2.8. Plasmid construction and dual-luciferase reporter assays
Partial wild-type sequences of the TPD52 30 untranslated region
(UTR) or those with a deleted miR-224 target site (position
Table 2
Downregulated genes in miR-224 transfectants and upregulated genes in GEO database.
Entrez gene
ID
Symbol Gene name Location PC3 miR-224
transfectant
DU145 miR-224
transfectant
Average GEO Fold
change
7163 TPD52 Tumor protein D52 8q21.13 1.385 2.896 2.141 0.607
7175 TPR Translocated promoter region (to activated MET
oncogene)
1q31.1 0.614 1.944 1.279 0.333
3930 LBR Lamin B receptor 1q42.12 1.092 1.064 1.078 0.215
81839 VANGL1 Vang-like 1 (van gogh, Drosophila) 1p13.1 1.439 0.690 1.065 0.455
80218 NAA50 N(alpha)-acetyltransferase 50, NatE catalytic
subunit
3q13.2 1.103 0.931 1.017 0.357
204 AK2 Adenylate kinase 2 1p35.1 1.061 0.893 0.977 0.129
5935 RBM3 RNA binding motif (RNP1, RRM) protein 3 Xp11.23 1.075 0.831 0.953 0.311
4155 MBP Myelin basic protein 18q23 0.782 1.091 0.936 0.314
57180 ACTR3B ARP3 actin-related protein 3 homolog B (yeast) 7q36.1 1.046 0.776 0.911 0.119
4591 TRIM37 Tripartite motif containing 37 17q22 0.539 1.262 0.900 0.475
23212 RRS1 RRS1 ribosome biogenesis regulator homolog (S.
cerevisiae)
8q13.1 1.590 0.148 0.869 0.634
10492 SYNCRIP Synaptotagmin binding, cytoplasmic RNA
interacting protein
6q14.3 1.068 0.606 0.837 0.165
10269 ZMPSTE24 Zinc metallopeptidase (STE24 homolog, S.
cerevisiae)
1p34.2 0.714 0.956 0.835 0.443
27230 SERP1 Stress-associated endoplasmic reticulum protein
1
3q25.1 0.540 0.992 0.766 0.258
8396 PIP4K2B Phosphatidylinositol-5-phosphate 4-kinase, type
II, beta
17q12 0.465 0.951 0.708 0.305
2521 FUS Fused in sarcoma 16p11.2 0.974 0.386 0.680 0.569
983 CDK1 Cyclin-dependent kinase 1 10q21.2 1.038 0.259 0.648 0.384
55023 PHIP Pleckstrin homology domain interacting protein 6q14.1 0.427 0.811 0.619 0.357
84187 TMEM164 Transmembrane protein 164 Xq23 0.498 0.732 0.615 0.354
6146 RPL22 Ribosomal protein L22 1p36.31 0.155 1.057 0.606 0.465
2317 FLNB Filamin B, beta 3p14.3 0.282 0.901 0.591 0.382
1964 EIF1AX Eukaryotic translation initiation factor 1A, X-
linked
Xp22.12 0.662 0.338 0.500 0.322
285268 ZNF621 Zinc ﬁnger protein 621 3p22.1 0.278 0.606 0.442 0.115
63933 CCDC90A Coiled-coil domain containing 90A 6p23 0.694 0.179 0.436 0.243
79184 BRCC3 BRCA1/BRCA2-containing complex, subunit 3 Xq28 0.243 0.617 0.430 0.345
220988 HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 2q31.2 0.277 0.463 0.370 0.513
808 CALM3 Calmodulin 3 (phosphorylase kinase, delta) 19q13.32 0.444 0.180 0.312 0.390
4644 MYO5A Myosin VA (heavy chain 12, myoxin) 15q21.2 0.122 0.433 0.278 0.406
9043 SPAG9 Sperm associated antigen 9 17q21.33 0.169 0.278 0.224 0.197
5814 PURB Purine-rich element binding protein B 7p13 0.102 0.259 0.180 0.185
Y. Goto et al. / FEBS Letters 588 (2014) 1973–1982 1977632–638 of the TPD52 30 UTR) were inserted between the XhoI–
PmeI restriction sites in the 30 UTR of the hRluc gene in the
psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). The syn-
thesised DNA was cloned into the psiCHECK-2 vector. PC3 cells
were transfected with 50 ng of the prepared vector and 10 nM
miR-224 using Lipofectamine 2000 (Invitrogen). The activities of
ﬁreﬂy and renilla luciferase in cell lysates were determined with
a dual-luciferase assay system (E1910; Promega). Normalised data
were calculated as the ratio of renilla/ﬁreﬂy luciferase activities as
described previously [9,13,14].
2.9. Statistical analysis
The relationships between 2 groups and the numerical values
obtained by qRT-PCR were analysed using the Mann–Whitney
U-test. The relationships among more than 3 variables and numer-
ical values were analysed using the Bonferroni-adjusted Mann–
Whitney U-test. All analyses were performed using Expert Stat-
View (version 5, SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. The expression of miR-224 in PCa specimens
First, we evaluated the expression of miR-224 in normal pros-
tate tissues (n = 38) and advanced PCa tissues (n = 50). Patients
with normal prostate tissues had a median PSA level of 7.3 ng/mL (range, 4.3–35.5 ng/mL), whereas PCa patients had higher PSA
values, with a median of 228 ng/mL (3.45–3750 ng/mL). PCa
patients had progressive disease, with 70.0% and 62.0% of patients
classiﬁed as N1 and M1, respectively, according to the TNM classi-
ﬁcation (Table 1).
To conﬁrm our prior PCa miRNA proﬁling results, we evaluated
miR-224 expression in advanced PCa specimens. The expression
level of miR-224 was signiﬁcantly lower in advanced PCa tissues
than in non-cancerous tissues (P < 0.0001; Fig. 1). Additionally,
PC3 and DU145 cells also exhibited lower expression of miR-224
than normal prostate tissues (Fig. 1).
3.2. Effects of miR-224 restoration on the proliferation, migration, and
invasion activities of PC3 and DU145 cells
To investigate the functional effects of miR-224, we performed
gain-of-function studies using miRNA transfection of PC3 and
DU145 cells. We used 2 sources of mature miR-224 (miR-224-A:
Ambion, miR-224-T: Thermo Scientiﬁc Dharmacon) to ensure the
reproducibility of the data.
XTT assays demonstrated that cell proliferation was not inhib-
ited in miR-224 transfectants in comparison with mock- or miR-
control-transfected cells (Fig. 2A). However, miR-224 transfection
signiﬁcantly inhibited cell migration as compared with mock- or
miR-control-transfected cells (Fig. 2B and Supplemental Fig. 1).
Similarly, Matrigel invasion assays demonstrated that cell invasion
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Fig. 3. Direct regulation of TPD52 bymiR-224. (A) TPD52mRNA expression was evaluated by qRT-PCR at 72 h after transfection withmiR-224. GAPDH was used as an internal
control. (B) TPD52 protein expression was evaluated by Western blotting at 72 h after transfection with miR-224. GAPDH was used as a loading control. (C) miR-224 binding
sites in the 30 UTR of TPD52 mRNA. Luciferase reporter assays were performed using a vector encoding putative miR-224 target sites at position 632–638 for both wild-type
(WT) and deletion (Del) constructs. Renilla luciferase values were normalised to ﬁreﬂy luciferase values. ⁄P < 0.05.
1978 Y. Goto et al. / FEBS Letters 588 (2014) 1973–1982activity was signiﬁcantly inhibited in miR-224 transfectants in
comparison with mock or miR-control transfectants (Fig. 2C and
Supplemental Fig. 2).
3.3. Identiﬁcation of candidate target genes of miR-224 in PCa cells
To identify target genes ofmiR-224, we performed in silico anal-
ysis and oligomicroarray analysis. The TargetScan program showed
that 3025 genes had putative target sites for miR-224 in their 30
UTR regions. To gain further insights into which genes were
affected by tumour-suppressive miR-224 in PCa, we performed
genome-wide gene expression analysis using PC3 and DU145 cells,
and genes downregulated (log2 ratio < 0.1) by miR-224 transfection
were selected. Finally, to identify upregulated genes in clinical PCa
specimens, we analysed a publicly available gene expression data
set in the GEO (accession number: GSE29079) and selected upreg-
ulated genes (log2 ratio > 0.1). Thirty candidate genes were identi-
ﬁed as targets of miR-224. Of these, the TPD52 gene was
downregulated following transfection with miR-224 (Table 2).
3.4. TPD52 was directly regulated by miR-224
Next, we performed qRT-PCR and Western blotting to conﬁrm
that restoration of miR-224 resulted in downregulation of TPD52
in PC3 and DU145 cells. The mRNA and protein expression levels
of TPD52 were signiﬁcantly repressed in miR-224 transfectants in
comparison with mock or miR-control transfectants (P < 0.005,
Fig. 3A and B).We then performed luciferase reporter assays in PC3 cells to
determine whether TPD52 mRNA was directly regulated by miR-
224. The TargetScan database predicted that one putative miR-
224-binding site existed in the 30 UTR of TPD52 (positions 632–
638, Fig. 3C). We used vectors encoding either the partial wild-type
sequence of the 30 UTR of TPD52 mRNA, including the predicted
miR-224 target sites, or ‘deletion’ vectors, that is, those lacking
themiR-224 target sites. We found that the luminescence intensity
was signiﬁcantly reduced by transfection with miR-224 and a vec-
tor carrying the wild-type 30 UTR of TPD52, whereas transfection
with deletion vectors (where nucleotides at positions 632–638
had been removed) blocked the decrease in luminescence
(P = 0.0002, Fig. 3C). These data suggested that miR-224 bound
directly to speciﬁc sites in the 30 UTR of TPD52 mRNA.
3.5. Effects of silencing TPD52 on cell proliferation, migration, and
invasion in PCa cell lines
To investigate the functional role of TPD52, we performed loss-
of-function studies using si-TPD52 transfectants. First, we evalu-
ated the knockdown efﬁciency of si-TPD52 transfection in PC3
and DU145 cells. Western blotting and qRT-PCR indicated that si-
TPD52 transfection effectively downregulated TPD52 expression
in PC3 and DU145 cells (Fig. 4).
In functional assays, cell proliferation was not inhibited by
transfection with si-TPD52 in comparison with mock- or si-
control-transfected PC3 and DU145 cells (Fig. 5A). However, migra-
tion (Fig. 5B and Supplemental Fig. 3) and invasion (Fig. 5C and
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1980 Y. Goto et al. / FEBS Letters 588 (2014) 1973–1982Supplemental Fig. 4) assays demonstrated that cell migration and
invasion activity were signiﬁcantly inhibited in si-TPD52 transfec-
tants in comparison with mock- or si-control-transfected PC3 and
DU145 cells.
3.6. Expression of TPD52 in PCa clinical specimens
Among 88 PCa and non-PCa samples, we selected RNA samples
that could be used for reverse transcription analysis of TPD52
mRNA expression. Finally, 12 PCa samples (Table 1, No. 39–50)
and 10 non-PCa samples (Table 1, No. 29–38) were subjected to
TPD52 mRNA expression analysis in this study. qRT-PCR analysis
showed that the expression of TPD52 mRNA was signiﬁcantly
higher in clinical PCa specimens than in non-PCa specimens
(P = 0.0006, Fig. 6A). In these 22 clinical specimens, Spearman’s
rank test showed that there was a negative correlation between
the expression of miR-224 and TPD52 (R = 0.452 and P = 0.0382,
Fig. 6B).
4. Discussion
Aberrant expression of miRNAs can disrupt the tightly regulated
system of miRNA-protein-coding RNA networks in cancer cells [6].
Therefore, studies of differentially expressed miRNAs in cancer
cells provide important information regarding the molecular
mechanisms underlying oncogenesis and metastasis. To elucidate
the molecular mechanisms underlying cancer metastasis, we
have performed several studies seeking to identify tumour-
suppressive miRNAs, focusing on the molecular targets and novel
cancer pathways that these miRNAs regulate based on expression
signatures [13,15,16]. Our recent studies of miRNAs in PCa have
demonstrated that miR-1, miR-133a, miR-143, and miR-145 func-
tion as tumour suppressors by targeting several oncogenic genes
[8–10]. These successful studies showed that our analysis strategy
was effective for identiﬁcation of novel oncogenic pathways regu-
lated by tumour-suppressive miRNAs in PCa cells.In this study, we conﬁrmed that miR-224 expression was
decreased in independent PCa clinical specimens. Additionally,
we examined the functional relevance of miR-224 using 2 different
types of maturemiR-224 in gain-of-function studies. We found that
restoration of mature miR-224 using these 2 constructs signiﬁ-
cantly inhibited cancer cell migration and invasion. These results
strongly suggested that miR-224 functioned as a tumour suppres-
sor in PCa cells. Downregulation of miR-224 has also been reported
in other types of human cancers, including ovarian, lung, and
breast cancers, in addition to PCa [17–21]. Additionally, one study
has shown that more aggressive PCa is associated with lower
expression ofmiR-224 and that downregulation of miR-224 is asso-
ciated with biochemical relapse [22]. More recently, a study dem-
onstrated that miR-224 downregulation was frequently found in
metastatic PCa tissues [23]. In contrast, several studies have dem-
onstrated thatmiR-224 is highly expressed in various cancers, such
as hepatocellular carcinoma [24–28], pancreatic ductal carcinoma
[29], colorectal cancer [25,30] and renal cell carcinoma [31]. Inter-
estingly, overexpression of miR-224 in hepatocellular carcinoma
contributes to the regulation of cell migration and invasion
[24,28,32], contradicting the data from our study of PCa. Therefore,
these results suggest that the molecular targets and networks reg-
ulated bymiR-224 depend on the type of cancer. Data on the differ-
ential expression of miR-224 and its target genes in human cancers
are summarised in Supplemental Table 1.
miRNAs are unique in their ability to regulate multiple protein-
coding genes. Bioinformatic predictions indicate that miRNAs reg-
ulate more than 30–60% of the protein-coding genes in the human
genome [33,34]. Reduced expression of tumour-suppressive miR-
NAs may cause overexpression of oncogenes in cancer cells.
Improving our understanding ofmiR-224-mediated targets and sig-
nalling pathways in PCa may provide important insights into the
mechanisms of PCa metastasis. To this end, we performed a com-
bination of genome-wide gene expression analysis and in silico
analysis. Recent miRNA studies in our laboratory have utilised this
strategy to identify novel molecular targets and pathways
Y. Goto et al. / FEBS Letters 588 (2014) 1973–1982 1981regulated by tumour-suppressive miRNAs in several cancers,
including PCa [8–10,13–16].
In this study, we selected 30 putative candidate genes regulated
by miR-224 and focused on the TPD52 gene as a responsible onco-
gene in PCa metastasis. TPD52 was originally cloned as a tumour-
associated antigen in breast cancer using SEREX screening [35].
Additionally, several groups have demonstrated that TPD52 is both
overexpressed and present in an ampliﬁed chromosomal region of
8q21 in ovarian cancer and PCa [11,36,37]. The human chromo-
some 8q21 region is one of the most frequently ampliﬁed regions
in PCa [12,38], suggesting that TPD52 may act as a candidate onco-
gene in PCa. Recent reports have shown that TPD52 is overexpres-
sed in several types of human cancers, both at the mRNA and
protein levels [39,40]. Other reports have demonstrated that the
prostate leucine zipper (PrLZ) gene, a member of the TPD52 family,
contains a C-terminal region identical to TPD52. The N-terminal
region of PrLZ contains an extended unique sequence of 46 amino
acid residues [41,42]. Several studies have shown that increased
expression of PrLZ enhances the growth of LNCaP cells under both
normal and CRPC conditions [43,44]. Our data demonstrated that
the miR-224-TPD52 axis contributed to cancer cell migration and
invasion, but did not affect cell proliferation. Previous reports have
indicated that exogenous TPD52 expression promotes prostate can-
cer cell migration via avb3 integrin through activation of the pro-
tein kinase B/Akt pathway [45]. This study supports our present
data and suggests that analysis of the signalling pathways down-
stream of the miR-224-TPD52 axis will be important to elucidate
the mechanisms of PCa cell metastasis.
This is the ﬁrst report to demonstrate that tumour-suppressive
miR-224 directly regulates oncogenic TPD52 in PCa cells. Further-
more, silencing of TPD52 resulted in signiﬁcant reductions in can-
cer cell migration and invasion in PC3 and DU145 cells. Taken
together, our data supported that downregulation of miR-224 dis-
rupts tightly regulated miRNA-protein coding RNA networks, one
of which is upregulation of TPD52, and that this event promotes
cancer cell migration and invasion in PCa cells. Conﬁrmation of
these data using an in vivo mouse model is essential to support
the conclusions of our in vitro results within the context of cancer
cell metastasis. Elucidation of oncogenic TPD52 pathways regu-
lated by tumour-suppressive miR-224 may reveal novel effective
therapeutic targets in the treatment of advanced PCa.
5. Conclusions
Our data showed that miR-224 was frequently downregulated
in PCa tissues and might be function as tumour suppressor in
PCa cells. Elucidation of cancer pathways regulated by tumour-
suppressive miR-224 should shed light on PCa metastasis and
delineate more effective strategies for future therapeutic interven-
tions for this disease.
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